

Kolliphor[®] SML 20

Pharmaceutical grade sorbitan laurate for topical and oral applications





Inspiring Medicines for Better Lives

Kolliphor[®] SML 20

Pharmaceutical grade sorbitan laurate for topical and oral applications

Kolliphor[®] SML 20 (sorbitan laurate) is a non-ionic, lipophilic surfactant and emulsifier for pharmaceutical applications, derived from the dehydration and esterification of sorbitol and lauric acid.

As a non-ethoxylated surfactant and emulsifier, Kolliphor® SML 20 can be used in a range of oral and topical dosage forms including capsules, tablets, suspensions, aerosols, foams, creams, gels, and more. While often acting as a solubilizing agent, this excipient can also act as an emulsifier for semi-solid products. Kolliphor® SML 20 has a long history of use in topical applications as an oil-in-water emulsifier for steric stabilized systems, but can also be used to formulate water-in-oil emulsions due to its low HLB value of 8.6.*

Figure 1. The represented formula is simplified showing the structure of sorbitan laurate, only.

RO RO RC ٦R



*The HLB can vary depending on variations in the absolute fatty acid composition. Based on the analyzed fatty acid distribution of three measured batches, HLB values of 8.6, 8.6 and 8.7 were calculated. A rounded HLB of 9 will be met for all batches provided by BASF."s

Kolliphor[®] SML 20

Product details

Generic name	Sorbitan laurate
CAS number	1338-39-2
Manufacturing site	Duesseldorf, Germany
Manufacturing process	Semi-synthetic
Regulatory	Ph. Eur.IPEC-PQG GMP for excipientsComplete pharma documentation available
Appearance	Brownish-yellow, viscous liquid
Certified	Kosher, Halal
PRD number	30776707
Packaging and article numbers	190 kg lacquered steel drum (ART 50728982)
Sample and article number	0.5 kg glass bottle (ART 50728983)
Retest period	24 months
Storage and transport	Store in the original packaging and below 30°C

Key customer benefits

Supply reliability	Product is globally available in 190 kg drums
Consistent quality	Ph. Eur. monograph compliance (Sorbitan Laurate)
Sustainability	Roundtable on Sustainable Palm Oil (RSPO) certification available
Technical service	 Deep understanding of excipient science Formulation guidance with ZoomLab™
BASF Virtual Pharma Assistants	 Regulatory documentation available in RegXcellence[®] Product details available in MyProductWorld

Full pharma regulatory documentation and submission support



Example cream formulation

A lightweight, quick-spreading cream for even skin application.

Phase	Ingredient	Chemical name	% (w/w)
	Kolliwax [®] CSA 50	Cetostearyl alcohol	7.00
	Kollisolv® MCT 70	Triglycerides, medium-chain	10.00
A	Kolliwax® GMS II	Glycerol monostearate 40-55 (type II)	2.00
	Kolliphor [®] SML 20	Sorbitan laurate	1.94
	Kolliphor [®] CS 20	Macrogol cetostearyl ether 20	1.56
	Water	Water	73.5
В	Glycerin	Glycerin	3.00
	Xanthan gum	Xanthan gum	0.30
С	Euxyl™ PE 9010	Phenoxyethanol-ethylhexylglycerin	0.70

Procedure

- 1. Weigh out phase A into an appropriately sized beaker. Place the mixture under an overhead mixer and set to 50 rpm. Heat the mixture to 70 – 80°C.
- 2. In a separate beaker, weigh out the water for phase B and heat to 70 80°C.
- 3. Add phase A to phase B under shear.
- 4. Homogenize mixture at 5000 rpm for 10 minutes.
- 5. Place the mixture under an overhead mixer and allow to cool under mild shear.
- 6. When the formulation has cooled to 45°C, add in the preservative (phase C).

Example lotion formulation

An easy-to-apply lotion offering a balance between gentleness and skin absorption.

Phase	Ingredient	Chemical name	% (w/w)
	Kolliwax [®] CSA 50	Cetostearyl alcohol	5.00
	Kollicream [®] IPM	Isopropyl myristate	10.00
A	Kolliwax [®] GMS II	Glycerol monostearate 40-55 (type II)	2.00
	Kolliphor [®] SML 20	Sorbitan laurate	1.00
	Kolliphor [®] CS 20	Macrogol cetostearyl ether 20	1.00
	Water	Water	77.00
В	Glycerin	Glycerin	3.00
	Xanthan gum	Xanthan gum	0.30
С	Euxyl™ PE 9010	Phenoxyethanol-ethylhexylglycerin	0.70

Procedure

- Weigh out phase A into an appropriately sized beaker. Place the mixture under an overhead mixer and set to 50 rpm. Heat the mixture to 70 – 80°C.
- 2. In a separate beaker, weigh out the water for phase B and heat to 70 80°C.
- 3. Add phase A to phase B under shear.
- 4. Homogenize mixture at 5000 rpm for 10 minutes.
- 5. Place the mixture under an overhead mixer and allow to cool under mild shear.
- 6. When the formulation has cooled to 45°C, add in the preservative (phase C).

Example gel formulation

A simple gel that offers a cooling sensation upon application.

Phase	Ingredient	Chemical name	% (w/w)
	Ethanol	Ethanol	10.00
A	Glycerin	Glycerin	5.00
	Kollisolv® PEG 400	Polyethylene glycol	12.00
	Kolliphor [®] SML 20	Sorbitan laurate	2.00
	Euxyl™ PE 9010	Phenoxyethanol-ethylhexylglycerin	1.00
В	Kolliphor [®] P 407	Poloxamer 407	18.00
	Water	Water	52.00

Procedure

- 1. Leave phase B refrigerated at 5 °C for 24 hours, or until all of the Kolliphor[®] P 407 has dissolved in the water.
- 2. Add phase A to phase B. Stir slowly until the poloxamer has gelled, being careful not to mix in excess air.

It's Time to Think about Sustainable Sourcing

BASF offers the widest range of IPEC-GMP lipid-based excipients, suitable for topical and oral drug formulations. We are committed to providing high quality products supported by best-in-class Regulatory, Quality, and Technical teams. We value sustainability and are the first major supplier to offer 100% RSPO-certified lipid-based excipients.

Join BASF in committing to sustainable sourcing for lipid-based pharmaceutical excipients

- Contribute significantly to your own sustainable sourcing efforts
 - Same high-quality, compendial lipid-based products with no physical or chemical changes
 - RSPO-certified lipid-based products

- Certificate numbers provided with every produced and delivered batch
 - Join BASF as part of RSPO to market your own products as RSPO-certified



Save time and avoid costly missteps with Virtual Pharma Assistants, your interactive guides to browsing ingredients, optimizing drug formulations, and navigating quality and regulatory compliance.

Sign up to access all three Virtual Assistants (RegXcellence[®], ZoomLab[™], MyProductWorld) to learn how our convenient and user-friendly guides support Kolliphor[®] SML 20 and our other multifunctional products.





Exceptional Quality & Regulatory Support



The Pharma Solutions Regulatory Team has a global and regional presence with a decades-long track record of enabling our Pharma customers to register finished drug products worldwide. We do this by efficiently offering high-quality expert solutions through proactive and transparent communication.

Our global Quality Team supports our customers worldwide with regards to any quality-related questions.

A regional footprint secures quick and regional-specific solutions in alignment with global standards for topics like audits, statements and complaints.

In close exchange with authorities and international associations, we are constantly improving our quality systems to provide the best service to our customers in more and more demanding markets. For this purpose we cooperate closely with the production sites and ensure GMP-compliant production and testing in accordance with the latest requirements of the pharmaceutical authorities.

Access to standard quality and regulatory documentation is now more efficient than ever. Retrieve your documents 24/7 from your WorldAccount or sign-up for new RegXcellence®, your free online Quality & Regulatory Assistant that provides a unified platform for compliance documents, filing assistance and audit information.



Sign-up today at: virtualpharmaassistants.basf.com

Contact us for pricing. pharma-solutions@basf.com

This document, or any information provided herein does not constitute a legally binding obligation of BASF and has been prepared in good faith and is believed to be accurate as of the date of issuance. Unless expressly agreed otherwise in writing in a supply contract or other written agreement between you and BASF:

(a) To the fullest extent not prohibited by the applicable laws, BASE EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, BY FACT OR LAW, INCLUDING ANY IMPLIED WARRANTIES, REPRESENTATIONS OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY OUALITY, NON-INFRINGEMENT, AND ANY REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES, ARISING FROM STATUTE, COURSE OF PARLING OR USAGE OF TRADE and BASE HEREBY EXPRESSLY EXCLUDES AND DISCLAIMS ANY LIABILITY RESULTING FROM OR IN CONNECTION WITH THIS DOCUMENT OR ANY INFORMATION PROVIDED HEREIN, including, without limitation, any liability for any direct, consequential, special, or punitive damages relating to or arising therefrom, except in cases of (i) death or personal injury to the extent caused by BASF's sole negligence, (ii) BASF's willful misconduct, fraud or fraudulent misrepresentation or (iii) any matter in respect of which it would be unlawful for BASF to exclude or restrict liability under the applicable laws (b) Any information

tion provided herein can be changed at BASF's sole discretion anytime and neither this document nor the information provided herein may be relied upon to satisfy from any and all obligations you may have to undertake your own inspections and evaluations; (c) BASF rejects any obligation to, and will not, automatically update this document and any information provided herein, unless required by applicable law; and (d) The user is responsible for confirming that the user has retrieved the most current version of this document from BASF as appropriate

© 2023 BASF

Inspiring Medicines for Better Lives

BASF_Pharma in BASF Pharma Solutions www.pharma.basf.com

We create chemistry